Clinical Trials Logo

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion clinical trials

View clinical trials related to Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion.

Filter by:
  • None
  • Page 1

NCT ID: NCT02824133 Suspended - Clinical trials for Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"

TARGET
Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators will look for the presence of the fusion gene in all patients operated on for glioma. This search will be limited to all gliomas that show no IDH1 mutation, the latter being sought in both routine and anomalies never co-existing. The hypothesis is that the rate of progression-free survival in grade IV gliomas and III without IDH1 mutation, with the usual chemotherapy, only 15% at 6 months (ie, 85% of patients relapse before 6 months of treatment), must be with this new treatment 35% (primary endpoint). The main objective is the evaluation of disease-free survival at 6 months.